Study on the Pathogenesis of Retinal Vascular Diseases Based on Body Fluid Metabolomics
NCT ID: NCT06408571
Last Updated: 2024-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
3900 participants
OBSERVATIONAL
2023-09-07
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Factors and Diabetic Retinopathy
NCT00005761
Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage
NCT06272565
A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema
NCT02876393
Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection
NCT07144865
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion
NCT00308477
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
Patients with retinal vein obstruction and diabetic retinopathy
etiology
As an important part of systems biology, metabolomics mainly detects various metabolites in the sample. Different from nucleic acids, proteins and other biological macromolecules, the relative molecular weight of these metabolites is small, generally within 1000Da, such as amino acids, carboxylic acids, carbohydrates, alcohols, amines, lipids and other special substances. Through qualitative and quantitative analysis of all endogenous low molecular weight metabolites before and after pathophysiology or gene modification stimulation, metabolomics reveals the essential characteristics of life activities and metabolism of the body, and provides guidance for exploring the pathogenesis, early diagnosis, treatment and prognosis of diseases.
Control group
Cataract surgery and vitrectomy patients
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
etiology
As an important part of systems biology, metabolomics mainly detects various metabolites in the sample. Different from nucleic acids, proteins and other biological macromolecules, the relative molecular weight of these metabolites is small, generally within 1000Da, such as amino acids, carboxylic acids, carbohydrates, alcohols, amines, lipids and other special substances. Through qualitative and quantitative analysis of all endogenous low molecular weight metabolites before and after pathophysiology or gene modification stimulation, metabolomics reveals the essential characteristics of life activities and metabolism of the body, and provides guidance for exploring the pathogenesis, early diagnosis, treatment and prognosis of diseases.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of retinal vein obstruction and diabetic retinopathy through ophthalmic specialist examination
Exclusion Criteria
* Pregnant and lactating patients
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhongnan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20240202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.